Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Recent Headlines for $RBCC
http://finance.yahoo.com/q/h?s=RBCC&ql=1
Good to see u on the board fast.money!
RBCC
I think so too, high volume today
$RBCC
Nice to see all the updates!
RBCC
Lots of great news out from RBCC lately!
http://finance.yahoo.com/q/p?s=RBCC+Press+Releases
We go higher from here!
RBCC
You know what that means? Boom-time soon!!
RBCC
I was just noticing that, good things coming here imo!
RBCC
Nice support here Hooka, double bottom
RBCC
RBCC to Make Addiction Therapy Affordable for Everyone
http://finance.yahoo.com/news/rbcc-addiction-therapy-affordable-everyone-090000258.html
RBCC
Should see GREEN tomorrow imo!
RBCC
Volume picking up too!
RBCC
Getting big buzz!
RBCC
This should move quickly!
rbcc
This pump and dump garbage company got me as well. Hopefully the SEC steps in soon.
$RBCC recent news/filings
bullish
oversold at support
strong volume during advances and small volume during pullbacks
people are accumulating for long term gains
## source: finance.yahoo.com
Wed, 26 Aug 2015 09:00:00 GMT ~ RBCC Offers Solution to Canada’s Growing Opioid Abuse Crisis
[Business Wire] - With more and more Canadians becoming hooked on prescription opioids, the federal government in Ottawa has started to consider limits and prescription monitoring programs to curb the growing abuse.
read full: http://finance.yahoo.com/news/rbcc-offers-solution-canada-growing-090000469.html
*********************************************************
Mon, 24 Aug 2015 09:00:00 GMT ~ RBCC Partner n3D Signs Research Sponsorship Agreement with Prominent Medical School
[Business Wire] - Rainbow Coral Corp. partner Nano3D Biosciences has just inked an important sponsored research agreement with the prestigious University of Texas Health Science Center at Houston Department of Obstetrics, Gynecology, and Reproductive Sciences.
read full: http://finance.yahoo.com/news/rbcc-partner-n3d-signs-research-090000991.html
*********************************************************
Wed, 19 Aug 2015 20:43:37 GMT ~ RAINBOW CORAL CORP. Files SEC form 10-Q, Quarterly Report
read full: http://biz.yahoo.com/e/150819/rbcc10-q.html
*********************************************************
Wed, 19 Aug 2015 09:00:00 GMT ~ RBCC Eagerly Following White House Plans to Counter Heroin/Painkiller Abuse
[Business Wire] - Rainbow Coral Corp. has taken note of the Obama Administration’s recent announcement of a new strategy to cut heroin and opiate use in several East Coast states. The company stands ready to assist and support Federal Medication Assisted Treatment programs utilizing Naltrexone, an important prescription drug used in treatment of heroin and opiate addiction.
read full: http://finance.yahoo.com/news/rbcc-eagerly-following-white-house-090000754.html
*********************************************************
Thu, 13 Aug 2015 09:00:00 GMT ~ Naltrexone for Opioid Addiction Spotlighted in Vermont Treatment Grant
[Business Wire] - Rainbow Coral Corp. hailed Vermont’s recent winning of a $3 million grant to aid opioid addiction treatment in the Green Mountain State, and pledged to provide support for similar Medication Assisted Treatment programs throughout the country utilizing Naltrexone.
read full: http://finance.yahoo.com/news/naltrexone-opioid-addiction-spotlighted-vermont-090000737.html
*********************************************************
$RBCC charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$RBCC company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/RBCC/company-info
Ticker: $RBCC
OTC Market Place: OTCQB
CIK code: 0001499790
Company name: Rainbow Coral Corp.
Company website: http://www.rainbowbiosciences.com
Incorporated In: FL, USA
Business Description: RAINBOW CORAL CORP. (the \"Company\") was formed to build a coral farm facility to develop and propagate (or grow) live coral, independent of the oceans, as a future farm reserve against the decline of natural wild reefs. We intend to grow, harvest, and distribute as many varieties of hard and soft sizes as possible of captive-bred corals that are attractive, to as many consumers as possible who can maintain them in a healthy ecosystem aquarium. We believe that coral and other marine aquarium livestock should be supplied by farms or captive breeders, rather than removed from the natural reefs. The additional uses for coral as a source of potential leading edge medical discoveries are an attractive opportunity for the Company's coral farming activity. We believe that the world of bioresearch is a natural continuation of our core coral propagation business. Accordingly, on October 23, 2011, the Company formed a subsidiary, Rainbow Biosciences, LLC to look into the opportunities within the bioscience market. Rainbow Biosciences, LLC will continue to research opportunities into the bioscience markets.The Company was incorporated in Florida on August 13, 2010. The Company's fiscal year end is March 31.On May 29, 2015, we reincorporated from Florida to Nevada. Each shareholder received one share in the Nevada company for each 100 shares they held in the Florida company. Fractional shares were rounded up, and each shareholder received at least five shares. The executive officers and directors of the Nevada company are unchanged from the executive officers and directors of the Florida company. All share and per share amounts have been retroactively restated to reflect the reverse split.Less >>
$RBCC share structure
## source: otcmarkets.com
Market Value: $12,056,720 a/o Aug 26, 2015
Shares Outstanding: 7,535,450 a/o Jul 13, 2015
Float: 956,973 a/o Jul 13, 2015
Authorized Shares: 480,000,000 a/o Jul 14, 2015
Par Value: Not Available
$RBCC extra dd links
Company name: Rainbow Coral Corp.
Company website: http://www.rainbowbiosciences.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=RBCC+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=RBCC+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=RBCC+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/RBCC/news - http://finance.yahoo.com/q/h?s=RBCC+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/RBCC/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/RBCC/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=RBCC+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/RBCC
DTCC (dtcc.com): http://search2.dtcc.com/?q=Rainbow+Coral+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Rainbow+Coral+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Rainbow+Coral+Corp.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.rainbowbiosciences.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.rainbowbiosciences.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.rainbowbiosciences.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/RBCC
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001499790&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/RBCC/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/RBCC/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=RBCC&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=RBCC
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/RBCC/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=RBCC+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=RBCC+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=RBCC
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=RBCC
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=RBCC+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/RBCC/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=RBCC+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/RBCC.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=RBCC
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/RBCC/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/RBCC
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/RBCC
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/RBCC:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=RBCC
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=RBCC
$RBCC DD Notes ~ http://www.ddnotesmaker.com/RBCC
No kidding, its a standard pump and dump
It doesn't get any smellier than this:
"the management team didn't renegotiate the terms of the convertible notes when they effected the reverse split which means that 86% of the currently issued and outstanding shares saw the light of day at just $0.02 apiece. Make sure you bear this in mind when you reach for your wallet."
https://www.hotstocked.com/article/90803/rainbow-coral-corp-otcmkts-rbcc-marches-on.html
Shorter's paradise at this level!
RBCC ditto on the chart but the trading action is somewhat telling. They aren't trying to hide their hand- constant gap ups on first print, one day's high is the next day's low etc. I'll be watching if more big blocks go off at the ask so as to continually increase (wash up) volume, thinking the guys running it may be getting ready to take profits...
Chart looking real nice here. 50dma big beautiful curl and heading for the 200. Another nice pop closer to the golden cross? Congrats to the longs that have been here under $1. This could be the play of the future.
"According to the press releases, Rainbow Coral Corp (OTCMKTS:RBCC) is a biotech company that's traded on the OTC Markets. Unlike most of the penny stocks in this industry, however, RBCC claims to have a “flagship” product. It's a drug called Naltrexone.
"It was originally developed to treat alcohol and opioid dependence, but RBCC said on Thursday that the list of applications is growing rapidly. Thanks to this, the stock shot up on Friday and it managed to gain an impressive 43%, finishing the week just north of the $3 per share mark.
"Based on all this, you're probably thinking that what we have here is one of the few success stories on the OTC Markets. That's not quite the case.
"Once you dig a bit further, you'll find RBCC's choice of words a bit peculiar. They say that Naltrexone is their “flagship drug”, but in reality, they have not been involved in its development at all. The company recently expressed its intent to distribute it in Canada and they've been talking about coming up with a delivery system for it, but that just about sums up the company's involvement with the drug. The word “Naltrexone” itself is absent from the latest 10-K.
"And since we mentioned the latest 10-K, we might as well give you a run down of the most important figures found in it:
- cash: $5,180
- current assets: $7,414
- current liabilities: $453,632
- yearly revenues: $128,133
- yearly net loss: $990,233
"Naltrexone certainly had nothing to do with it, but RBCC did generate some revenues during the twelve months ended March 31 and you're probably wondering where they came from. The management team isn't too keen on telling us explicitly how they're generating their revenue, but they do say that the company owns and operates a fish store in Venice, Florida, and they also say that the year-over-year sales increase is due to “a remodeling of the front showroom”. Whether the showroom in question belongs to the said fish store and whether RBCC has any operations in the biotech industry as a whole remains unknown.
"Things are not looking good, and you might be a bit perplexed by the rather lofty share price at the moment. You shouldn't be. It can be explained with the 1 for 100 reverse split that the company effectuated at the end of May. This, by the way, brings us on to the biggest problem.
"Even if you decide to disregard the questions around the company's business completely, you have to consider the convertible notes that are starting to weigh down on the stock and its share structure. Unlike the majority of penny stocks out there, RBCC's debt can be turned into shares at fixed prices rather than a discount to the market value. The fixed prices range from $0.007 to $0.04 per share and this, it must be said, didn't sound too unreasonable prior to the reverse split when the ticker was struggling to stay out of the sub-penny levels.
"Curiously enough, however, when they effected the reverse split, the management team did absolutely nothing to alter the terms of the convertible notes. As a result, on June 1, when RBCC hovered around $0.51 per share, some lucky note holders received a total of 6,513,344 shares as a conversion of $125,059 worth of debt. In other words, about 86% of RBCC's issued and outstanding stock saw the light of day at a rate of just $0.02 per share."
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10807732
$RBCC recent news/filings
bullish
## source: finance.yahoo.com
Thu, 16 Jul 2015 09:00:00 GMT ~ RBCC: Naltrexone’s Growing List of Applications and Uses Expands Its Market Potential
[Business Wire] - Biotech company Rainbow Coral Corp. reports its flagship drug Naltrexone continues to gain widespread acceptance in the medical world as researchers discover more and more practical and beneficial uses for it.
read full: http://finance.yahoo.com/news/rbcc-naltrexone-growing-list-applications-090000571.html
*********************************************************
Wed, 15 Jul 2015 10:03:01 GMT ~ RAINBOW CORAL CORP. Files SEC form 10-K, Annual Report
read full: http://biz.yahoo.com/e/150715/rbcc10-k.html
*********************************************************
Thu, 09 Jul 2015 09:00:00 GMT ~ RBCC Nears Major Agreement to Distribute Naltrexone in Canada
[Business Wire] - Biotech company Rainbow Coral Corp. is drawing closer to a milestone agreement with a partner company to distribute Naltrexone – an important prescription drug used in treatment of alcohol and opiate addiction – in Canada.
read full: http://finance.yahoo.com/news/rbcc-nears-major-agreement-distribute-090000852.html
*********************************************************
Sat, 27 Jun 2015 17:04:08 GMT ~ RAINBOW CORAL CORP. Financials
read full: http://finance.yahoo.com/q/is?s=rbcc
*********************************************************
Tue, 02 Jun 2015 09:00:00 GMT ~ RBCC Explores New Pharmaceutical Compounding Opportunities in Booming Personalized Medicine Industry
[Business Wire] - As Rainbow Coral Corp. works to diversify its rapidly growing biotech business, the company is exploring new opportunities to provide innovative new products and services to the pharmaceutical compounding industry.
read full: http://finance.yahoo.com/news/rbcc-explores-pharmaceutical-compounding-opportunities-090000222.html
*********************************************************
$RBCC charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$RBCC company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/RBCC/company-info
Ticker: $RBCC
OTC Market Place: OTCQB
CIK code: 0001499790
Company name: Rainbow Coral Corp.
Company website: http://www.rainbowbiosciences.com
Incorporated In: FL, USA
Business Description: RAINBOW CORAL CORP. (the ?Company?), a Florida corporation, was formed to build a coral farm facility to develop and propagate (or grow) live coral, independent of the oceans, as a future farm reserve against the decline of natural wild reefs. We intend to grow, harvest and distribute as many varieties of hard and soft sizes as possible of captive-bred corals that are attractive, to as many consumers as possible who can maintain them in a healthy ecosystem aquarium. We believe that coral and other marine aquarium livestock should be supplied by farms or captive breeders, rather than removed from the natural reefs. The additional uses for coral as a source of potential leading edge medical discoveries are an attractive opportunity for the Company?s coral farming activity. We believe that the world of bio-research is a natural continuation of our core coral propagation business. Accordingly on October 23, 2011, the Company formed a subsidiary, Rainbow Biosciences, LLC to look into the opportunities within the bioscience market. Rainbow Biosciences, LLC will continue to research opportunities into the bioscience markets.The Company was incorporated on August 13, 2010 with its corporate headquarters located in Miramar Beach, Florida. The Company?s fiscal year end is March 31.Less >>
$RBCC share structure
## source: otcmarkets.com
Market Value: $718,416 a/o Jul 16, 2015
Shares Outstanding: 7,535,450 a/o Jul 13, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$RBCC extra dd links
Company name: Rainbow Coral Corp.
Company website: http://www.rainbowbiosciences.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=RBCC+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=RBCC+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=RBCC+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/RBCC/news - http://finance.yahoo.com/q/h?s=RBCC+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/RBCC/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/RBCC/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=RBCC+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/RBCC
DTCC (dtcc.com): http://search2.dtcc.com/?q=Rainbow+Coral+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Rainbow+Coral+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Rainbow+Coral+Corp.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.rainbowbiosciences.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.rainbowbiosciences.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.rainbowbiosciences.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/RBCC
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001499790&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/RBCC/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/RBCC/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=RBCC&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=RBCC
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/RBCC/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=RBCC+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=RBCC+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=RBCC
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=RBCC
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=RBCC+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/RBCC/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=RBCC+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/RBCC.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=RBCC
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/RBCC/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/RBCC/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/RBCC
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/RBCC
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/RBCC:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=RBCC
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=RBCC
$RBCC DD Notes ~ http://www.ddnotesmaker.com/RBCC
One item....in fact, the ONLY item from the 10K that matters:
In connection with the 1 for 100 reverse common stock split on May 29, 2015, the conversion rates of the outstanding convertible notes [to Vista Ventures] payable were not modified. As a result, in the event all potentially issuable shares were converted, the holders of the existing notes at March 31, 2015 would be issued 27,458,608 shares of common stock representing approximately 99% of the Company’s total shares outstanding on an if-converted basis.
In other words, because the convertible notes were not modified (ie reduced by a factor of 100), the effects of the 1:100 reverse split resulted in vista Ventures instantly receiving 100 times more value for their convertible notes!!
Vista Ventures is controlled by Thomas Cloud, son of the late penny king scamster JT Cloud. Vista Ventures is administered by Kathleen M. Delaney, also a long time scam queen among many other stinky pinkies.
$RBCC continues big pps rise on low volume. Now a 4 bagger at 2.00 in last 2 weeks. No news. Just a nice recovery from losses due to RS. Still a ways to go to get back value from those losses.
No trading since the RS. Probably due to no one getting their RS shares back in their accounts.
Yup - 1:100 Reverse Split announced: http://otce.finra.org/DailyList
****WARNING WARNING REVERSE SPLIT COMING****
$RBCC Vol continues to pour in. 58 x avg now. Need news to confirm this move. +68% to .0235.
It's in the 8K........et z
When is the RS gonna happen?
RBCC is doing a 1-100 Reverse Split. And THIS is how they phrased it...It's a GIFT....lol...too effing funny....wow
Sneaky little bastards huh?
ITEMS OF BUSINESS
Proposal I:
Reincorporation from Florida to Nevada that will result in:
· the company being governed by the laws of the State of Nevada;
· your right to receive one whole share of common stock of Rainbow Coral Nevada for each 100 shares of common stock of the Company owned by you as of the effective date of the reincorporation;
· adoption of Nevada articles of incorporation to authorize the issuance of preferred stock with preferences, limitations, and relative rights designated by our board of directors; and
. adoption of Nevada bylaws.
z
Followers
|
18
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
963
|
Created
|
10/25/11
|
Type
|
Free
|
Moderators |
Company Overview
http://www.rainbowbiosciences.com
Rainbow Biosciences is headquartered in the city of Houston, home of the largest medical complex in the world - the Texas Medical Center. In addition to some of the country's top research hospitals and facilities, Houston is home to more than 160 biotechnology companies and academic partnerships.
RBCC has begun to leverage these resources, delivering the newest and most sought-after biotech innovations to the scientific and medical communities.
RBCC is currently in talks with a promising company based in Houston, Texas, the home of the Texas Medical Center. The undisclosed company at current holds rights to eleven patents originally issued by NASA with a range of expertise from stem cell research to cancer and back to sickle cell anemia. Once the partnership is finalized, the two companies will work together to tap into the adult stem cell research industry - a market that is expected to reach a worth of $2.4 billion by 2015.
Partners
http://www.n3dbio.com
Rainbow Biosciences, LLC - a division of Rainbow Coral Corp. (RBCC) - is a new company focused on identifying, developing and marketing the next generation of bioscience solutions for the healthcare and scientific communities.
The company reached a major milestone recently in acquiring a new equity interest in emerging biotech game-changer Nano3D Biosciences (n3D). Nano3D's incredible new product, the Bio-Assembler, will soon allow researchers to dramatically shorten the development timeline for advanced new drugs and treatments while generating massive returns to investors.
In partnering with n3D, RBCC is poised for explosive growth in the biotech market, becoming a major new source of cutting-edge innovation.
The company is exploring several other opportunities within this sector, creating a rare opportunity for investors to become part of a multi-billion dollar industry just as it begins to take off.
Read More - http://www.n3dbio.com/products
Recent News - http://finance.yahoo.com/news/rbcc-partner-n3d-could-revolutionize-100000742.html
Possible AMBS Joint Venture
In an exciting new development, RBCC has signed a Letter of Intent (LOI) with an emerging industry powerhouse, Amarantus Biosciences, Inc. This is a company that's focused on developing diagnostics and therapeutics to tackle Parkinson's and other neurologic, degenerative diseases. Over 6 million patients worldwide suffer from Parkinson's. With RBCC, the company hopes to make that number zero.
http://www.rainbowbiosciences.com/amarantus.html
Read More - http://www.rainbowbiosciences.com/investors.html
11/09/2012 - RBCC Outline Terms with AMBS for Join Venture Project!
http://finance.yahoo.com/news/rbcc-amarantus-biosciences-outline-terms-165800932.html
http://origin-www.bloomberg.com/apps/news?pid=conewsstory&tkr=AMBS:US&sid=a54RARvR1UVw
Rainbow Coral Corp. is a fully reporting SEC company, publicly traded on the OTC Market under the symbol, "RBCC", and within the OTCQB market tier. As such, Business, Operational, and Financial information on Rainbow Coral Corp. is fully transparent and available to public view.
Visit: http://www.otcmarkets.com/stock/RBCC/company-info to see complete details.
Rainbow Coral Corp. - is Active on the Florida Secretary of State site:
http://sunbiz.org/scripts/cordet.exe?action=DETFIL&inq_doc_number=P10000066914&inq_came_from=NAMFWD&cor_web_names_seq_number=0000&names_name_ind=&names_cor_number=&names_name_seq=&names_name_ind=&names_comp_name=RAINBOWCORAL&names_filing_type=
A/S: 250 Million
O/S: 11.4 Million - as of 2/15/13
(Please note the share structure posted is what we have gathered but can change on a daily basis. Contact the Company or Transfer Agent to get the most current information.)
Their latest 10-Q Quarterly Report:
Filed on 2/19/13 ~ For the period ending 12/31/12
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9100326
Incorporated In: Florida in 2011
Transfer Agent:
Island Stock Transfer
15500 Roosevelt Boulevard
Suite 301
Clearwater, FL 33760
Phone: 727-289-0010
Email: info@islandstocktransfer.com
Website: http://www.islandstocktransfer.com
Disclaimer: The following Press Releases have not been investigated by Wall Street Surfers, therefore we have no idea if the content of this news is based on Fact or Fiction. Although the links for the following press releases may be from a familiar and reputable company , you should NOT assume that a press wire hosted by a website you are familiar with is accurate just because it is on their site. Wall Street Surfers will not be held responsible for any news release including and not limited to misleading or non-factual content, or the accuracy of the identity of the given source of the press release.
Business Wire - (February 6)
RBCC: n3D Technology Could Lead to Lab-Grown Implantable Organs
http://finance.yahoo.com/news/rbcc-n3d-technology-could-lead-100000571.html
Business Wire - (January 30)
RBCC Partner N3D Could Revolutionize Toxicity Testing
http://finance.yahoo.com/news/rbcc-partner-n3d-could-revolutionize-100000742.html
Business Wire - (December 19)
RBCC's Pending JV Partner Amarantus Licenses Alzheimer's Blood Test Breakthrough
http://finance.yahoo.com/news/rbcc-pending-jv-partner-amarantus-100000111.html
Business Wire - (December 3)
RBCC Issues Shareholder Letter Celebrating Promising 2013
http://finance.yahoo.com/news/rbcc-issues-shareholder-letter-celebrating-100000838.html
Contact Us:
Rainbow Coral Corporation
495 Grand Blvd. - Suite 206
Miramar Beach, FL 32550
Phone: 850-269-6801
Website: http://www.rainbowbiosciences.com/contact.html
Rainbow Coral Corp. (RBCC), via wholly owned subsidiary Rainbow Biosciences, continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. The company specifically pursues opportunities that offer short-term marketability and commercialization potential in key areas like Alzheimer's, Parkinson's, and Cancer.
Bioscience technology is a growing, dynamic field of innovation that applies life processes to practical uses, such as the manufacturing of medical devices and the development of new bioscience procedures. From pharmaceuticals to pacemakers, genetically engineered plants to gene therapy, bioscience technology can be found virtually anywhere.
The pending joint venture with Amarantus BioScience to develop and market new therapies and treatments for neurological diseases and physical traumas is a great example of the initiatives underway. In recent news, Amarantus licensed a highly promising diagnostic blood test that could become an invaluable new tool in Alzheimer's clinical trials where patient recruitment errors occur often due to inaccurate diagnosis.
The global biotech industry, currently valued at more than $84.6B, allows new players with bright ideas to quickly grab market share and create completely new markets. The exciting initiatives being driven forward by Rainbow Coral promise to transition today's leading-edge research into practical, affordable treatments for people who need them most.
Contact
495 Grand Boulevard
Suite 206
Miramar Beach, Fl 32550
Tel. (850) 269-6801
www.RainbowSciences.com
In September 2012, RBCC announced that the deal pipeline was once again open and that we would be expanding the focus of culturing 3D cell clusters to include adult as well. This massive market opens the door for promising new technologies that could potentially save hundreds of thousands - if not millions - of lives over the course of the next five to ten years. In addition, we are dedicated to bringing three promising new deals to the table by the end of 2012. We're starting with a promising stem cell target. Adult stem cells are important for two major reasons. First, they are able to be harvested directly from the host that needs them which means that there is an almost zero chance of rejection from the recipient. Also, with stem cells, more is often better in order to achieve the best growth. With the host available for this, it ups the chance of success in growth, too. Second, the black tape that surrounds stem cells continues to be the largest drawback. But adult stem cell research has been around for years with quite positive results. While it was once believed that adult stem cells did not offer the plasticity of embryonic, scientists now think they could be as versatile which would allow adult cells to solve just as many problems as embryonic - without the controversy. |
A NEW PARTNERSHIP COULD NET LARGE REWARDS RBCC is currently in talks with a promising company based in Houston, Texas, the home of the Texas Medical Center. The undisclosed company at current holds rights to eleven patents originally issued by NASA with a range of expertise from stem cell research to cancer and back to sickle cell anemia. Once the partnership is finalized, the two companies will work together to tap into the adult stem cell research industry - a market that is expected to reach a worth of $2.4 billion by 2015. Invest in RBCC today and tap into the possibilities of the stem cell research industry! |
As an emerging biotech company, Rainbow Biosciences is focusing on the development of explosive biotech and healthcare solutions that could change the way we approach life-threatening and life-altering diseases. In an exciting new development, RBCC has signed a Letter of Intent (LOI) with an emerging industry powerhouse, Amarantus Biosciences, Inc. This is a company that's focused on developing diagnostics and therapeutics to tackle Parkinson's and other neurologic, degenerative diseases. Over 6 million patients worldwide suffer from Parkinson's… With RBCC, the company hopes to make that number zero. People suffering from traumatic brain injuries, complications from stroke, and disorders associated with endoplasmic stress rely on the breakthroughs Amarantus and RBCC are poised to deliver. The symptoms of Parkinson's disease can vary from mild to severe. Tremors, stiff muscles, poor balance, slowness in voluntary movement and other symptoms can significantly impair the quality of life for a patient. Parkinson's affects 1% of people over the age of 55. However, there is also an increasing trend of young onset Parkinson's that affects patients under the age of 40. But there's hope. Once a definitive deal is signed, the two companies will be positioned to bring a proprietary new Parkinson's treatment to the market, and possibly, cure the disease. RBCC is more than just a great investment. As an early investor, you could play a role in delivering a sustainable treatment option to neurologically-affected patients around the world. |
ON THE BRINK OF WIPING OUT PARKINSON'S FOREVER! It may sound like science-fiction, but RBCC's new target Amarantus BioScience, Inc., owns the rights to a cutting-edge treatment that may be the key to a making Parkinson's a thing of the past. |
Once a definitive deal is signed, RBCC and Amarantus Biosciences, Inc. will continue working in the development of the novel, evolutionally-conversed, widely-expressed neuro-protective human growth factor known as MANF. This proprietary therapeutic protein works by preventing a type of cell death known as apoptosis. MANF could reverse the underlying neuropathology of Parkinson's disease, as well as permanently reverse symptoms. There are over 1.5 Parkinson's disease patients in the U.S. alone, filling drug prescriptions and over 6 million patients worldwide. RBCC's will be positioned to bring new, more effective treatment options to the market, which will provide an amazing opportunity for investment success. The increasing trend toward a longer lifespan coupled with the aging baby-boomer population means the incidence of PD is likely to double in the next 20 years. There are currently no treatments that stop or slow disease progression and there hasn't been a major breakthrough in treating the disease in decades. Thanks to cutting-edge biotech solutions from companies like Amarantus, RBCC and its investors will be able to capitalize on the growing number of people who are dependent upon treatments that can improve their lives. Sales of Parkinson's treatments were more than $3 billion in 2011. Analysts say that the demand for these treatment options in European and Japanese markets is exploding year over year. Perpetual growth opportunities and a solid business plan - RBCC has the tools needed for early success. Invest in RBCC today! |
RBCC: BREAKTHROUGH INNOVATIONS MEAN BIG RETURNS The treatment of cancer, Alzheimer's disease, and even spinal cord injuries has come a long way in recent years. People around the globe now look to cutting-edge science to find a cure for these kinds of chronic diseases and life-altering injuries. Rainbow Biosciences (RBCC) is on a mission to deliver better treatments and potential cures through aggressive research and innovation. The market for bioscience is booming. Companies in the biotech sector alone saw $25 billion in profits in 2010, a 15 percent jump from the previous record seen in 2007. This biotech boom is showing no signs of slowing down. Exciting new breakthroughs are already on the horizon. Researchers at the University of Southern California recently used nanotechnology to build a carbon nanotube synapse circuit that replicates the function of a neuron. Since neurons are major building blocks of the brain, this means that ultimately we are much closer to creating synthetic brain tissue. This type of technology may one day reverse the ill effects of Alzheimer's disease and brain trauma (Source: futurist.com). Join RBCC in its endeavors to capitalize on scientific breakthroughs that could change our outlook, our health, and our global economy for the better. Invest in RBCC today! |
ACCORDING TO THE EXPERTS... According to a 2011 report by Visiongain, the market for Parkinson's disease drugs could grow to a value of $3.75 billion by 2015; Amarantus is working on a candidate in the disease-modifying drug class which, if successful, could grab significant market share as well as substantially grow the overall Parkinson's drug market. There are currently no diagnostic tests available for Parkinson's disease, thus making Amarantus' test a first of its kind product capable of gaining a market leading position. RBCC expects that the consummation of a transaction contemplated in this LOI would position RBCC to capitalize on that growth. Invest in RBCC today! |
Researchers funded by the Biotechnology and Biological Sciences Research Council (BBSRC), among others, have taken the first step in developing a new type of vaccine to protect chickens against coccidiosis, the most important parasite of poultry globally. A vaccine of this type -- based on proteins from the coccidiosis bug rather than being derived from a live parasite -- could be produced on a larger scale than is currently possible, enabling more widespread protection for chicken flocks. Protecting against animal diseases is going to play an important role in ensuring global food security. Professor Douglas Kell, BBSRC Chief Executive, said "Finding new ways to combat diseases of farmed animals is going to be important to ensure global food security -- but also to the UK economy…This work is a nice example of how studying the fundamental biology of a process at the most minute level could lead to new weapons in the fight against disease."(Excerpt from Science Daily - A Step Towards New Vaccines for Most Important Chicken Parasite) |
LEVERAGING INNOVATION TO MEET DEMAND RBCC is moving forward rapidly in its initiatives to deliver treatments that not only save lives, but improve the lives of people all over the world. We have decided to move forward with a term sheet to be presented to an emerging Parkinson's drug therapy company that we're targeting for a potential acquisition. This new partnership would allow RBCC to develop diagnostics and therapeutics for Parkinson's disease as well as for patients suffering from traumatic brain injuries. Six million people worldwide suffer from Parkinson's-that number could be significantly reduced once these therapy solutions are moved out of the lab and into the marketplace. RBCC continues to forge connections with local academic and industry experts to promote translational and commercially viable research. Our company is poised for explosive growth in this exciting global market! From pharmaceuticals to pacemakers, genetically engineered plants to gene therapy, bioscience technology is at work all around us. RBCC is working to bring cutting-edge treatments to people who need them while delivering huge returns to investors. Invest today to become a part of this new biotech revolution! |
|
Celgene Corp. has agreed to invest $20 million to extend an exclusive partnership with private drug maker Agios Pharmaceuticals. The company received a $130 million upfront payment, including an equity investment to develop a novel class of cancer drugs that inhibit cancer cells from feeding themselves. After reading positive data from a study of its lead Hepatitis C drug, Roche purchased San Diego-based Anadys Pharmaceuticals for $230 million. Agricultural giant Monsanto will utilize Cloudant, leading architects & operators of 'big data' technology, to accelerate genome sequencing data analysis in crops. Pharmakon Advisors, LP, is seeking to invest an additional $363 million in assets secured by cash flows generated from sales of life sciences products. This amount is in addition to the $263 million that Pharmakon has already invested since June 2009. |
Bioscience technology is a growing, dynamic field of innovation that applies life processes to practical uses, such as the manufacturing of medical devices and the development of new bioscience procedures. From pharmaceuticals to pacemakers, genetically engineered plants to gene therapy, bioscience technology is at work all around us. This technology is used to develop novel approaches and medicines in disease treatment (such as the clinical use of interferon in treating cancer through regulated DNA alteration). Additionally, synthetically-produced therapeutics such as Human Growth Hormone and insulin are among others that benefit from recent biotechnological advances. New high-yield, cost-effective production routes are also being researched to produce monoclonal antibodies that have demonstrated an efficacious potential in a number of clinical treatments (Source: Society of Bioscience and Technology). The sky is the limit for RBCC's future initiatives because we're dedicated to transitioning leading-edge research into practical, affordable treatments for people who need them. Investors who stake their claim early in the bioscience market will claim the biggest early returns. Invest in RBCC today! |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |